High potency APIs are becoming a key focus of the pharmaceutical business, with drug makers from all areas racing to establish a foothold in the market.
From big pharma to generics manufacturers, it seems the molecules – which often prove to be more effective at smaller dosage levels than traditional APIs – are a highly sought after entity.
However, with the toxic nature of the ingredients, developing and manufacturing HPAPIs (high potency APIs) often presents companies with complex and sometimes unsolvable challenges.
Nevertheless companies such as Roche , Solvias and RohnerChem , and Carbogen Amcis are just a few of the firms that have recently waded further into the high potency market with new partnerships and facilities, signaling HPAPIs remain firmly on the horizon.
in-PharmaTechnologist asked the experts where they see the future of the business at last month’s AAPS conference in Washington.
GlaxoSmithKline’s (GSK) Allan Clarke, director of innovative manufacturing, spoke of the key role liquid media is now playing for the company.
And Dr. Reddy’s CPS Formulations project manager, Radha Srikrishna Maganti, told us how his firm is stressing the importance of classification of the molecules.